Plasmacytoid dendritic cell

Five distinct molecular endotypes were identified.

These endotypes differed in the activity of immune pathways, including PDC signatures, interferon signaling, granulocyte and monocyte activity, B cell and T cell pathways, and inflammatory cytokine programs.

Importantly, despite these biological differences, improvements in skin disease activity were observed across all molecular endotypes.

This suggests that the clinical benefit of litifiblimab is not limited to a s-- or not limited to a single molecular subtype of CLE and supports a broad treatment effect across diverse patient population.

And there is an ongoing phase three trial that is looking at patients with cutaneous lupus so that the drug would be accessible to more than just SLE patients.

So where do plasmacytoid dendritic cells, or PCCs, fit into that pathway? And why have they attracted attention as an upstream therapeutic target in lupus?

I think this is a wonderful question.

And we've known for a long time that the plasmacytoid dendritic cells are key cells in the production of type 1 interferon in the setting of viral infections.

And we've known that now for decades.

And the question is, what is the role of the PDC in the production of type 1 interferon in SLE or CLE.

And looking forward, the researchers suggest that the path to that recalibration lies in specific immune cells.

Future studies need to focus on plasmacytoid dendritic cells, or PDCs.

PDCs, okay.

Yeah,

these are rare specialized immune cells that act as the body's major professional interferon factories.

And their function is heavily dependent on IRF7.

Mapping out exactly how this specific risk haplotype behaves inside PDCs is the next logical step to fully unraveling the pathway for targeted therapies.

That makes sense.